阿斯特拉加卢斯多糖类通过正常化神经肌肉导电来改善糖尿病膀功能障碍
Shaochan Liang1, Siyuan Xu1,2,3, ShengLian Ye1
1School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
Journal of agricultural and food chemistry
|March 3, 2025
概括
阿斯特拉加卢斯多糖 (APS) 通过使神经肌肉导电正常化,有效地治疗糖尿病低活性膀 (UAB). 这项研究表明,APS在糖尿病小鼠中改善了膀功能和神经传递.
科学领域:
- 药理学 药理学是指药理学的学科.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 糖尿病学 糖尿病学
背景情况:
- 功能不良的膀 (UAB) 是糖尿病 (DM) 的并发症.
- 目前糖尿病UAB的药理治疗方法有限.
- 来自*Astragalus membranaceus*的阿斯特拉加勒斯多糖 (APS) 在糖尿病及其并发症方面表现有前途.
研究的目的:
- 在小鼠中研究APS对高脂肪饮食诱导的糖尿病UAB的影响和机制.
- 评估APS对糖尿病UAB的神经肌肉传导和神经递质的影响.
主要方法:
- 在使用高脂肪饮食 (HFD) 的小鼠中诱导糖尿病UAB.
- 向HFD诱导的糖尿病小鼠给予APS.
- 对血糖控制的评估 (快速的血葡萄糖,胰岛素,HOMA-IR).
- 评估膀功能参数 (容量,残留体积,符合性,压力,排泄效率).
- 检测神经肌肉收缩和神经递质水平 (nNOS,VIP,CHAT,SP) 的分析.
主要成果:
- 在HFD小鼠中,APS显著降低了高血糖和改善了胰岛素抵抗.
- APS治疗使膀容量,服从性,压力和排泄效率正常化.
- 在纯能和胆能介导的解器收缩中,APS改善了低反应性.
- 通过对nNOS和VIP进行下调和对ChAT和SP进行上调,APS调节了神经传递.
结论:
- 阿斯特拉加勒斯的多糖可以改善糖尿病引起的膀功能低下.
- APS使神经肌肉传导正常化,改善肌肉功能和神经传递.
- APS代表了一种潜在的治疗药物,用于治疗糖尿病UAB.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
485
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
111
相关概念视频
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
142
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
142
01:17Drugs for Treatment of Diarrhea-Predominant IBS
139
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
139
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
202
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
202